# Pluto Bio

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/pluto-bio

- Industry: Biotechnology
- Headquarters: Golden, US
- Website: www.pluto.bio/
- Total disclosed funding: $6.7M
- Latest round: Seed (Apr 21, 2025)
- Investors on record: 2

## About

Pluto Biosciences, Inc. is a US-based company specializing in advanced multi-omics platforms that enhance translational discovery in biological research, focusing on bioinformatics tools for analyzing complex biological data.Founded in 2020 and headquartered in Golden, US, Pluto Biosciences, Inc. develops a multi-omics platform aimed at improving biological research. The company was founded by Rani Powers, who has a history of involvement in the biotech sector. Pluto Biosciences has engaged in three funding rounds, with the latest being a Seed round on April 21, 2025, raising USD 3.000 mn from Kickstart Capital, Silverton Partners, and individual investors. The total amount raised since inception is USD 3.000 mn, and the company's current valuation stands at USD 18.299 mn.Pluto Biosciences offers an advanced multi-omics platform designed to facilitate translational discovery in biological research. The platform includes sophisticated bioinformatics tools that enable researchers to analyze and visualize complex biological data, featuring an intuitive no-code interface that streamlines workflows for a range of biological assays including single-cell RNA sequencing (scRNA-seq), RNA-Seq, ChIP-seq, CUT&RUN, and proteomics. The service enhances interdisciplinary collaboration among scientific teams, allowing efficient tracking of experiments, data annotation, and generation of publication-ready visualizations. Pluto Biosciences caters to a diverse client base that includes pharmaceutical companies, biotechnology firms, academic institutions, and contract research organizations (CROs) across North America, Europe, and Asia, addressing the increasing demand for accelerated drug discovery and biomarker identification.Pluto Biosciences employs a subscription-based revenue model for access to its multi-omics platform, facilitating direct B2B transactions. Clients can select from various service tiers tailored to their specific research needs, which may include partnerships for custom bioinformatics support. The pricing structure corresponds with the complexity and scale of the analyses required, allowing various institutions to utilize the platform for projects ranging from small academic studies to expansive pharmaceutical research. The company also engages in collaborations with industry partners to enhance its offerings by integrating additional services or features into its suite, positioning itself as a comprehensive solution in the life sciences sector.Following the Seed funding round completed on April 21, 2025, in which Pluto Biosciences raised USD 3.000 mn, the company plans to invest in the development of AI agents and copilots, expand integrations with R&D tools, build out commercial roles, and accelerate its deployment across various therapeutic areas. Pluto also aims to launch new products that enhance its platform capabilities, targeting expansion into additional global markets by the end of 2026.

## Funding rounds

- Seed, Apr 21, 2025, $3M — Kickstart, Silverton Partners
- Seed, May 1, 2023, $3.7M — Silverton Partners

## Investors

- Silverton Partners (https://capitalatlas.ai/funds/silverton-partners) — Seed
- Kickstart (https://capitalatlas.ai/funds/kickstart) — Seed